{"success":true,"data":{"pressRelease":{"id":"155896","rtpr_id":"nGNE4F7rVx-20260929","ticker":"CUPR","exchange":"NASDAQ","all_tickers":["CUPR"],"title":"Cuprina Holdings (Cayman) Limited Announces Closing of Underwriter’s Over-Allotment Option in Connection with Public Offering","author":"Globe Newswire","published_at":"2026-09-29T20:00:00.221Z","article_body":"SINGAPORE, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman)\nLimited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical\ncompany developing and marketing products for the chronic wounds, infertility,\nmedical waste recycling, and cosmeceuticals sectors, today announced that it\nclosed the sale of an additional 648,373 Class A ordinary shares of the\nCompany, pursuant to the full exercise of the underwriter’s over-allotment\noption granted in connection with the Company’s public offering (“PO”,\ntogether with such over-allotment closing, the “Offering”), at a public\noffering price of $1.15 per share, for a total of approximately $745,629 of\ngross proceeds to the Company, before deducting underwriting discounts and\noffering expenses. As a result, the Company has raised aggregate gross\nproceeds of approximately $5,716,491, including the previously announced PO\ngross proceeds of approximately $4,970,862, prior to deducting underwriting\ndiscounts and commissions and estimated offering expenses payable by the\nCompany.\n\nThe Company intends to use net proceeds from the Offering for expansion into\nnew businesses, R&D activities to expand its product offerings, growth and\nexpansion into new markets, building brand awareness, investment in equipment\nand infrastructure, and working capital and general corporate purposes.\n\nR. F. Lafferty & Co., Inc. (“R. F. Lafferty”), acted as the sole\nbook-running manager for the Offering. Loeb & Loeb LLP, Lee & Lee, Harney\nWestwood & Riegels Singapore LLP are acting as U.S., Singapore and Cayman\nIslands legal counsels to the Company, respectively, and Ellenoff Grossman &\nSchole LLP is acting as U.S. legal counsel to R. F. Lafferty for the Offering.\n\nThe Offering is being conducted pursuant to the Company’s Registration\nStatement on Form F-1 (File No: 333-297299) previously filed with and\nsubsequently declared effective by the U.S. Securities and Exchange Commission\n(“SEC”) on September 15, 2026. The Offering is being made only by means of\na prospectus. Before you invest, you should read the prospectus and other\ndocuments the Company has filed or will file with the SEC for more information\nabout the Company and the Offering. Copies of the final prospectus related to\nthe Offering may be obtained, from R. F. Lafferty & Co., Inc., 40 Wall Street,\nSuite 3602, New York, NY 10005; (212) 293-9090, or by email at\nofferings@rflafferty.com. In addition, a copy of the final prospectus relating\nto the Offering may be obtained via the SEC’s website at www.sec.gov.\n\nThis press release has been prepared for informational purposes only and shall\nnot constitute an offer to sell or the solicitation of an offer to buy any of\nthe Company’s securities, nor shall such securities be offered or sold in\nthe United States absent registration or an applicable exemption from\nregistration, nor shall there be any offer, solicitation or sale of these\nsecurities in any state or jurisdiction in which such offer, solicitation or\nsale would be unlawful prior to registration or qualification under the\nsecurities laws of any such state or other jurisdiction.\n\nAbout Cuprina Holdings (Cayman) Limited\n\nWe are a Singapore-based biomedical and biotechnology company that is\ndedicated to the development and commercialization of innovative products for\nthe management of chronic wounds, as well as operating in the infertility,\nmedical waste recycling, and health and beauty sectors. Our expertise in\nbiomedical research allows us to identify and utilize materials derived from\nnatural sources to develop wound care products in the form of medical devices\nwhich meet international standards. For more information, please visit\nhttps://www.cuprina.com.\n\nFORWARD-LOOKING STATEMENTS\n\nCertain statements contained in this press release about future expectations,\nplans and prospects, as well as any other statements regarding matters that\nare not historical facts, may constitute “forward-looking statements”\nwithin the meaning of the Private Securities Litigation Reform Act of 1995.\nThese statements include, but are not limited to, statements relating to the\ngross proceeds of the offering. The words “anticipate,” “believe,”\n“continue,” “could,” “estimate,” “expect,” “intend,”\n“may,” “plan,” “potential,” “predict,” “project,”\n“should,” “target,” “will,” “would” and similar expressions\nare intended to identify forward-looking statements, although not all\nforward-looking statements contain these identifying words. Actual results may\ndiffer materially from those indicated by such forward-looking statements as a\nresult of various important factors, including: the uncertainties related to\nmarket conditions and the completion of the public offering on the anticipated\nterms or at all, and other factors discussed in the “Risk Factors” section\nof the preliminary prospectus filed with the SEC. For these reasons, among\nothers, investors are cautioned not to place undue reliance upon any\nforward-looking statements in this press release. Any forward-looking\nstatements contained in this press release speak only as of the date hereof,\nand Cuprina Holdings (Cayman) Limited specifically disclaims any obligation to\nupdate any forward-looking statement, whether as a result of new information,\nfuture events or otherwise, except as required by law.\n\nCuprina Holdings (Cayman) Limited Investor Contact\n\nInvestor Relations\nc/o Blk 1090 Lower Delta Road #06-08\nSingapore 169201\n+65 8512 7275\nEmail: ir@cuprina.com.sg","article_body_html":"","raw_payload":{"data":{"id":"nGNE4F7rVx-20260929","title":"Cuprina Holdings (Cayman) Limited Announces Closing of Underwriter’s Over-Allotment Option in Connection with Public Offering","author":"Globe Newswire","ticker":"CUPR","created":"2026-09-29T20:00:00.221Z","tickers":["CUPR"],"exchange":"NASDAQ","article_body":"SINGAPORE, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman)\nLimited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical\ncompany developing and marketing products for the chronic wounds, infertility,\nmedical waste recycling, and cosmeceuticals sectors, today announced that it\nclosed the sale of an additional 648,373 Class A ordinary shares of the\nCompany, pursuant to the full exercise of the underwriter’s over-allotment\noption granted in connection with the Company’s public offering (“PO”,\ntogether with such over-allotment closing, the “Offering”), at a public\noffering price of $1.15 per share, for a total of approximately $745,629 of\ngross proceeds to the Company, before deducting underwriting discounts and\noffering expenses. As a result, the Company has raised aggregate gross\nproceeds of approximately $5,716,491, including the previously announced PO\ngross proceeds of approximately $4,970,862, prior to deducting underwriting\ndiscounts and commissions and estimated offering expenses payable by the\nCompany.\n\nThe Company intends to use net proceeds from the Offering for expansion into\nnew businesses, R&D activities to expand its product offerings, growth and\nexpansion into new markets, building brand awareness, investment in equipment\nand infrastructure, and working capital and general corporate purposes.\n\nR. F. Lafferty & Co., Inc. (“R. F. Lafferty”), acted as the sole\nbook-running manager for the Offering. Loeb & Loeb LLP, Lee & Lee, Harney\nWestwood & Riegels Singapore LLP are acting as U.S., Singapore and Cayman\nIslands legal counsels to the Company, respectively, and Ellenoff Grossman &\nSchole LLP is acting as U.S. legal counsel to R. F. Lafferty for the Offering.\n\nThe Offering is being conducted pursuant to the Company’s Registration\nStatement on Form F-1 (File No: 333-297299) previously filed with and\nsubsequently declared effective by the U.S. Securities and Exchange Commission\n(“SEC”) on September 15, 2026. The Offering is being made only by means of\na prospectus. Before you invest, you should read the prospectus and other\ndocuments the Company has filed or will file with the SEC for more information\nabout the Company and the Offering. Copies of the final prospectus related to\nthe Offering may be obtained, from R. F. Lafferty & Co., Inc., 40 Wall Street,\nSuite 3602, New York, NY 10005; (212) 293-9090, or by email at\nofferings@rflafferty.com. In addition, a copy of the final prospectus relating\nto the Offering may be obtained via the SEC’s website at www.sec.gov.\n\nThis press release has been prepared for informational purposes only and shall\nnot constitute an offer to sell or the solicitation of an offer to buy any of\nthe Company’s securities, nor shall such securities be offered or sold in\nthe United States absent registration or an applicable exemption from\nregistration, nor shall there be any offer, solicitation or sale of these\nsecurities in any state or jurisdiction in which such offer, solicitation or\nsale would be unlawful prior to registration or qualification under the\nsecurities laws of any such state or other jurisdiction.\n\nAbout Cuprina Holdings (Cayman) Limited\n\nWe are a Singapore-based biomedical and biotechnology company that is\ndedicated to the development and commercialization of innovative products for\nthe management of chronic wounds, as well as operating in the infertility,\nmedical waste recycling, and health and beauty sectors. Our expertise in\nbiomedical research allows us to identify and utilize materials derived from\nnatural sources to develop wound care products in the form of medical devices\nwhich meet international standards. For more information, please visit\nhttps://www.cuprina.com.\n\nFORWARD-LOOKING STATEMENTS\n\nCertain statements contained in this press release about future expectations,\nplans and prospects, as well as any other statements regarding matters that\nare not historical facts, may constitute “forward-looking statements”\nwithin the meaning of the Private Securities Litigation Reform Act of 1995.\nThese statements include, but are not limited to, statements relating to the\ngross proceeds of the offering. The words “anticipate,” “believe,”\n“continue,” “could,” “estimate,” “expect,” “intend,”\n“may,” “plan,” “potential,” “predict,” “project,”\n“should,” “target,” “will,” “would” and similar expressions\nare intended to identify forward-looking statements, although not all\nforward-looking statements contain these identifying words. Actual results may\ndiffer materially from those indicated by such forward-looking statements as a\nresult of various important factors, including: the uncertainties related to\nmarket conditions and the completion of the public offering on the anticipated\nterms or at all, and other factors discussed in the “Risk Factors” section\nof the preliminary prospectus filed with the SEC. For these reasons, among\nothers, investors are cautioned not to place undue reliance upon any\nforward-looking statements in this press release. Any forward-looking\nstatements contained in this press release speak only as of the date hereof,\nand Cuprina Holdings (Cayman) Limited specifically disclaims any obligation to\nupdate any forward-looking statement, whether as a result of new information,\nfuture events or otherwise, except as required by law.\n\nCuprina Holdings (Cayman) Limited Investor Contact\n\nInvestor Relations\nc/o Blk 1090 Lower Delta Road #06-08\nSingapore 169201\n+65 8512 7275\nEmail: ir@cuprina.com.sg"},"type":"article","timestamp":"2026-09-29T20:00:00.353052242Z","server_sent_at_ms":1790712000353},"received_at":"2026-09-29T20:00:00.464Z","source_url":null},"analysis":null,"durationMs":null,"modelName":null}}